Neurological

PE-22-28

Research Reagent · Laboratory Use Only

Quick Answer

How does PE-22-28 produce rapid antidepressant-like effects in preclinical models?

PE-22-28 is a synthetic heptapeptide analogue of spadin that inhibits the TREK-1 two-pore-domain potassium channel in cortical and serotonergic neurons. TREK-1 blockade increases neuronal excitability and serotonergic tone, producing antidepressant-like effects in rodent models within 4 days versus the 2-3 week onset of conventional SSRIs.

PMID30048756↗DOI10.1016/j.bbr.2018.07.013↗⟳ Reconstitution Calculator
Scientific AbstractPMID 30048756 · 2018

PE-22-28 is a synthetic seven-amino-acid analogue of spadin, a peptide derived from the propeptide region of sortilin. Preclinical research demonstrates that PE-22-28 inhibits the TREK-1 two-pore-domain potassium channel, which is highly expressed in neurons of the prefrontal cortex, hippocampus, and serotonergic raphe nuclei. TREK-1 blockade increases neuronal excitability and serotonergic tone, producing rapid antidepressant-like effects in rodent models within 4 days, contrasting with the 2-3 week onset of conventional SSRIs. Research has explored both intravenous and intranasal administration routes.

Source:10.1016/j.bbr.2018.07.013
Mechanistic Research SummaryCurated from PubMed

This data is for laboratory research purposes only. Not for human or animal consumption.

What is PE-22-28?

PE-22-28 is a synthetic heptapeptide analogue of spadin investigated in preclinical models for rapid-onset antidepressant activity through TREK-1 channel inhibition.

Mechanism of Action

PE-22-28 selectively inhibits the TREK-1 two-pore-domain potassium channel in cortical, hippocampal, and serotonergic raphe neurons, increasing neuronal excitability and serotonergic tone.

Observed Laboratory Results

  • Antidepressant-like effects in rodent models within 4 days versus 2-3 weeks for SSRIs
  • TREK-1 selectivity distinguishing it from broader-spectrum potassium channel blockers
  • Activity via intranasal and IV routes demonstrated in preclinical pharmacokinetic work
Clinical Research ParametersHuman Study Registry

No registered clinical trials or indexed human study data currently available for PE-22-28 via ClinicalTrials.gov or PubMed. This compound may be at preclinical or early research stages.

Search ClinicalTrials.gov ↗Search PubMed ↗
Research Compliance Notice

All data presented on this page is for laboratory research purposes only. PE-22-28 is referenced here as a research reagent. This page does not constitute medical advice, clinical guidance, or endorsement of any compound for human or animal use. All referenced studies are available via PubMed (PMID: 30048756) and the DOI-linked journal publication. Researchers must consult applicable institutional and regulatory frameworks before conducting any protocols.

Related Compounds

Other Neurological Research Compounds

Semax
Alzheimer's disease, first described over a century ago, is currently among the most commo…
→
Selank
BACKGROUND: Primary Sjögren's disease (SjD) is a chronic autoimmune disease that predomina…
→
Cerebrolysin
Previous studies from our laboratory show that intraperitoneal injections of 1-metyl-4-phe…
→
Dihexa
BACKGROUND: Huntington's disease (HD) is a neurodegenerative disorder characterized by mot…
→
View all Neurological compounds →